Abigail E. Overacre-Delgoffe

Abigail E. Overacre-Delgoffe

Auto-generated profile, based on publicly available information

Abigail E. Overacre-Delgoffe

Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2013 in Nature
Verified
Journal Article
Open access
PDF file
GDGreg M. Delgoffe
Greg M. Delgoffe
SWSeng-Ryong Woo
Seng-Ryong Woo
MTMeghan E. Turnis
Meghan E. Turnis
DGDavid M. Gravano
David M. Gravano
CGCliff Guy
Cliff Guy
DVDario A. A. Vignali
Dario A. A. Vignali
Neuropilin-1 (Nrp1) on regulatory T (Treg) cells is shown to interact with semaphorin-4a (Sema4a) to promote a program of Treg-cell stability and survival, in part through PTEN-mediated modulation of Akt signalling; Nrp1-deficient Treg cells can maintain immune homeostasis but fail to suppress in inflammatory sites, such as tumours, providing an attractive immunotherapeutic target for the treatment of cancers. Regulatory T cells (Treg) constitute a barrier to effective anti-tumour immunity. Their depletion can induce reduction and clearance of many tumours, but as the cells perform an important balancing role in the immune system, depletion also results in unchecked autoimmunity and death. This paper describes an interaction between semaphorin-4a — an activator for T-cell-mediated immunity — and the neuropilin receptor Nrp1 on Treg cells that is required for Treg cells to limit anti-tumour immune responses and to cure established inflammatory colitis, but is dispensable for suppression of autoimmunity and maintenance of immune homeostasis. It remains to be determined whether it is feasible to limit tumour growth by targeting Treg cells without unleashing autoimmunity. The two biological activities may be inseparable, but this work points to ways in which this important system can be further characterized. Regulatory T cells (Treg cells) have a crucial role in the immune system by preventing autoimmunity, limiting immunopathology, and maintaining immune homeostasis1. However, they also represent a major barrier to effective anti-tumour immunity and sterilizing immunity to chronic viral infections1. The transcription factor Foxp3 has a major role in the development and programming of Treg cells2,3. The relative stability of Treg cells at inflammatory disease sites has been a highly contentious subject4,5,6. There is considerable interest in identifying pathways that control the stability of Treg cells as many immune-mediated diseases are characterized by either exacerbated or limited Treg-cell function. Here we show that the immune-cell-expressed ligand semaphorin-4a (Sema4a) and the Treg-cell-expressed receptor neuropilin-1 (Nrp1) interact both in vitro, to potentiate Treg-cell function and survival, and in vivo, at inflammatory sites. Using mice with a Treg-cell-restricted deletion of Nrp1, we show that Nrp1 is dispensable for suppression of autoimmunity and maintenance of immune homeostasis, but is required by Treg cells to limit anti-tumour immune responses and to cure established inflammatory colitis. Sema4a ligation of Nrp1 restrained Akt phosphorylation cellularly and at the immunologic synapse by phosphatase and tensin homologue (PTEN), which increased nuclear localization of the transcription factor Foxo3a. The Nrp1-induced transcriptome promoted Treg-cell stability by enhancing quiescence and survival factors while inhibiting programs that promote differentiation. Importantly, this Nrp1-dependent molecular program is evident in intra-tumoral Treg cells. Our data support a model in which Treg-cell stability can be subverted in certain inflammatory sites, but is maintained by a Sema4a–Nrp1 axis, highlighting this pathway as a potential therapeutic target that could limit Treg-cell-mediated tumour-induced tolerance without inducing autoimmunity.

3 February 2013 in Nature Immunology
Verified
Journal Article
Open access
CGClifford S Guy
Clifford S Guy
KVKate M Vignali
Kate M Vignali
JTJamshid Temirov
Jamshid Temirov
MBMatthew L Bettini
Matthew L Bettini
AOAbigail E Overacre
Abigail E Overacre
DVDario A A Vignali
Dario A A Vignali
The physiological basis and mechanistic requirements for a large number of functional immunoreceptor tyrosine-based activation motifs (ITAMs; high ITAM multiplicity) in the complex of the T cell antigen receptor (TCR) and the invariant signaling protein CD3 remain obscure. Here we found that whereas a low multiplicity of TCR-CD3 ITAMs was sufficient to engage canonical TCR-induced signaling events that led to cytokine secretion, a high multiplicity of TCR-CD3 ITAMs was required for TCR-driven proliferation. This was dependent on the formation of compact immunological synapses, interaction of the adaptor Vav1 with phosphorylated CD3 ITAMs to mediate the recruitment and activation of the oncogenic transcription factor Notch1 and, ultimately, proliferation induced by the cell-cycle regulator c-Myc. Analogous mechanistic events were also needed to drive proliferation in response to weak peptide agonists. Thus, the TCR-driven pathways that initiate cytokine secretion and proliferation are separable and are coordinated by the multiplicity of phosphorylated ITAMs in TCR-CD3.

2 March 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
TMThomas U Marron
Thomas U Marron
ARAideen E Ryan
Aideen E Ryan
SRSangeetha M Reddy
Sangeetha M Reddy
SKSabina Kaczanowska
Sabina Kaczanowska
RYRania H Younis
Rania H Younis
JGJennifer Guerriero
Jennifer Guerriero
Immune checkpoint inhibitors (ICIs) have improved overall survival for cancer patients, however, optimal duration of ICI therapy has yet to be defined. Given ICIs were first used to treat patients with metastatic melanoma, a condition that at the time was incurable, little attention was initially paid to how much therapy would be needed for a durable response. As the early immunotherapy trials have matured past 10 years, a significant per cent of patients have demonstrated durable responses; it is now time to determine whether patients have been overtreated, and if durable remissions can still be achieved with less therapy, limiting the physical and financial toxicity associated with years of treatment. Well-designed trials are needed to identify optimal duration of therapy, and to define biomarkers to predict who would benefit from shorter courses of immunotherapy. Here, we outline key questions related to health, financial and societal toxicities of over treating with ICI and present four unique clinical trials aimed at exposing criteria for early cessation of ICI. Taken together, there is a serious liability to overtreating patients with ICI and future work is warranted to determine when it is safe to stop ICI.

8 December 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
CCChristopher A. Chuckran
Christopher A. Chuckran
ACAnthony R. Cillo
Anthony R. Cillo
JMJessica Moskovitz
Jessica Moskovitz
AOAbigail Overacre-Delgoffe
Abigail Overacre-Delgoffe
ASAshwin S. Somasundaram
Ashwin S. Somasundaram
DVDario A. A. Vignali
Dario A. A. Vignali
Persistent T cell receptor stimulation drives neuropilin-1 on intratumoral regulatory T cells, which is associated with poor clinical outcome.

13 February 2013 in European Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
KSKazuko Sakata
Kazuko Sakata
JMJoshua R. Mastin
Joshua R. Mastin
SDSean M. Duke
Sean M. Duke
MVMeghan G. Vail
Meghan G. Vail
AOAbigail E. Overacre
Abigail E. Overacre
SJShanker Jha
Shanker Jha

30 July 2025 in Cancer Discovery
Verified
Journal Article
Open access
KMKristin M. Morder
Kristin M. Morder
MNMadison Nguyen
Madison Nguyen
DWDrew N. Wilfahrt
Drew N. Wilfahrt
ZDZakaria Larbi Dahmani
Zakaria Larbi Dahmani
ABAnsen B.P. Burr
Ansen B.P. Burr
AOAbigail E. Overacre-Delgoffe
Abigail E. Overacre-Delgoffe
Gut microbiota composition is directly associated with response to immunotherapies in cancer. The impact of diet on the gut microbiota and downstream immune responses to cancer remains unclear. In this study, we show that consumption of a common nonnutritive sweetener, sucralose, modifies microbiome composition, restricts T-cell metabolism and function, and limits immunotherapy response in preclinical models of cancer and patients with advanced cancer treated with anti–PD-1–based immune checkpoint inhibitors. Sucralose consumption is associated with a reduction in microbiota-accessible arginine, and amino acid supplementation or fecal microbiome transfer from anti–PD-1 responder mice completely restores T-cell function and immunotherapy response. Overall, sucralose consumption destabilizes the gut microbiota, resulting in compromised T-cell function and ablated immune checkpoint inhibitor response in cancer. Significance: This study highlights an unappreciated role of sucralose in reducing immunotherapy efficacy in both mouse models and samples from patients with cancer through shifts in the microbiome and arginine degradation that lead to T-cell exhaustion. T-cell function and immunotherapy responses are restored through amino acid supplementation. See related commentary by Chandra et al., p. 2196